The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis-Reference-Cited by-同舟云学术

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

Published:2015-09-24 Issue:13 Volume:126 Page:1551-1554
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Deininger Michael¹,Radich Jerald²,Burn Timothy C.³,Huber Reid³,Paranagama Dilan³,Verstovsek Srdan⁴

Affiliation:

1. University of Utah Huntsman Cancer Institute, Salt Lake City, UT;

2. Fred Hutchinson Cancer Research Center, Seattle, WA;

3. Incyte Corporation, Wilmington, DE; and

4. The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract

Key Points The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/13/1551/1388527/1551.pdf

Reference18 articles.

1. Advances in understanding and management of myeloproliferative neoplasms.;Vannucchi;CA Cancer J Clin,2009

2. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.;Levine;Nat Rev Cancer,2007

3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.;Pikman;PLoS Med,2006

4. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.;Scott;N Engl J Med,2007

5. Somatic mutations of calreticulin in myeloproliferative neoplasms.;Klampfl;N Engl J Med,2013

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

3. Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine;Cancers;2024-04-26

4. Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms;Nature Communications;2024-04-06

5. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms;American Journal of Hematology;2024-03-05